Effects of Liraglutide in Young Adults With Type 2 DIAbetes (LYDIA)
Status:
Completed
Trial end date:
2017-09-29
Target enrollment:
Participant gender:
Summary
There are recent advances in therapies for the treatment of Type 2 Diabetes Mellitus (T2DM)
which include the GLP1 analogues and the DPP IV inhibitors. Both of these therapies target
the incretin system using different methods to elevate/maintain circulating levels of GLP1 to
subsequently achieve improved blood sugar control. Interestingly, GLP1 analogues have been
reported not only to improve blood sugar control but to additionally induce weight-loss and
emerging experimental evidence has shown it may have beneficial effects on the heart's
structure and function. Due to the profile of this condition being a lot worse and younger
patients having greater CVD risk, a therapy offering multiple positive effects, in particular
the potential cardiometabolic effects, make this line of therapy attractive in this patient
population.
The aim of this research is to investigate the cardiometabolic effects of Liraglutide (GLP1
analogue) compared to that of its clinically relevant comparator Sitagliptin (DPP IV
inhibitor).